Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification of Trypanocidal Activity for Known Clinical Compounds Using a New Trypanosoma cruzi Hit-Discovery Screening Cascade
Manu De Rycker, John Thomas, Jennifer Riley, et al.
PLoS neglected tropical diseases (2016) Vol. 10, Iss. 4, pp. e0004584-e0004584
Open Access | Times Cited: 70

Showing 1-25 of 70 citing articles:

Screening the Medicines for Malaria Venture Pathogen Box across Multiple Pathogens Reclassifies Starting Points for Open-Source Drug Discovery
Sandra Duffy, Melissa L. Sykes, Amy J. Jones, et al.
Antimicrobial Agents and Chemotherapy (2017) Vol. 61, Iss. 9
Open Access | Times Cited: 131
Mechanism of Action of Miltefosine on Leishmania donovani Involves the Impairment of Acidocalcisome Function and the Activation of the Sphingosine-Dependent Plasma Membrane Ca 2+ Channel
Andrea Pinto-Martínez, Jessica Rodríguez-Durán, Xenón Serrano-Martín, et al.
Antimicrobial Agents and Chemotherapy (2017) Vol. 62, Iss. 1
Open Access | Times Cited: 105
Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery
Lorna MacLean, John Thomas, Michael D. Lewis, et al.
PLoS neglected tropical diseases (2018) Vol. 12, Iss. 7, pp. e0006612-e0006612
Open Access | Times Cited: 95
Phenotypic screening approaches for Chagas disease drug discovery
Eric Chatelain, Jean‐Robert Ioset
Expert Opinion on Drug Discovery (2017) Vol. 13, Iss. 2, pp. 141-153
Closed Access | Times Cited: 83
Drug repositioning approaches to parasitic diseases: a medicinal chemistry perspective
Leonardo L. G. Ferreira, Adriano D. Andricopulo
Drug Discovery Today (2016) Vol. 21, Iss. 10, pp. 1699-1710
Closed Access | Times Cited: 78
Disruption of Intracellular Calcium Homeostasis as a Therapeutic Target Against Trypanosoma cruzi
Gustavo Benaím, Alberto Paniz‐Mondolfi, Emilia Mia Sordillo, et al.
Frontiers in Cellular and Infection Microbiology (2020) Vol. 10
Open Access | Times Cited: 52
The translational challenge in Chagas disease drug development
Jadel M. Kratz, Karolina Ribeiro Gonçalves, Lavínia MD Romera, et al.
Memórias do Instituto Oswaldo Cruz (2022) Vol. 117
Open Access | Times Cited: 38
Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities
Exequiel O. J. Porta, Karunakaran Kalesh, Patrick G. Steel
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 21
State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation
Juan Carlos Gabaldón-Figueira, Nieves Martínez-Peinado, Elisa Escabia, et al.
Research and Reports in Tropical Medicine (2023) Vol. Volume 14, pp. 1-19
Open Access | Times Cited: 19
Frequency Variation and Dose Modification of Benznidazole Administration for the Treatment of Trypanosoma cruzi Infection in Mice, Dogs, and Nonhuman Primates
Juan M. Bustamante, Brooke E. White, Gregory K. Wilkerson, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 67, Iss. 5
Open Access | Times Cited: 17
Drugs in preclinical and early clinical development for the treatment of Chagas´s disease: the current status
Fernanda Karoline Vieira da Silva Torchelsen, Ana Lia Mazzeti, Vanessa Carla Furtado Mosqueira
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 6, pp. 575-590
Closed Access | Times Cited: 7
New drug discovery strategies for the treatment of benznidazole-resistance in Trypanosoma cruzi , the causative agent of Chagas disease
Silvane Maria Fonseca Murta, Pedro Augusto Lemos Santana, Thibault Joseph William Jacques Dit Lapierre, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 6, pp. 741-753
Closed Access | Times Cited: 6
Repositioning salicylanilide anthelmintic drugs to treat adenovirus infections
José Antonio Marrugal‐Lorenzo, Ana Serna‐Gallego, Judith Berastegui‐Cabrera, et al.
Scientific Reports (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 52
High Throughput and Computational Repurposing for Neglected Diseases
H. Hernandez, Melinda Soeung, Kimberley M. Zorn, et al.
Pharmaceutical Research (2018) Vol. 36, Iss. 2
Open Access | Times Cited: 51
Effective drug discovery in Chagas disease
Rick L. Tarleton
Trends in Parasitology (2023) Vol. 39, Iss. 6, pp. 423-431
Closed Access | Times Cited: 13
Current and promising novel drug candidates against visceral leishmaniasis
Rosa M. Reguera, Yolanda Pérez‐Pertejo, Camino Gutiérrez-Corbo, et al.
Pure and Applied Chemistry (2019) Vol. 91, Iss. 8, pp. 1385-1404
Open Access | Times Cited: 42
Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruzi
Stephen Brand, Eun Jung Ko, Elisabet Viayna, et al.
Journal of Medicinal Chemistry (2017) Vol. 60, Iss. 17, pp. 7284-7299
Open Access | Times Cited: 41
Drug Discovery for Chagas Disease: Impact of Different Host Cell Lines on Assay Performance and Hit Compound Selection
Caio Haddad Franco, Laura Maria Alcântara, Eric Chatelain, et al.
Tropical Medicine and Infectious Disease (2019) Vol. 4, Iss. 2, pp. 82-82
Open Access | Times Cited: 41
Discovery of Novel 7-Aryl 7-Deazapurine 3′-Deoxy-ribofuranosyl Nucleosides with Potent Activity against Trypanosoma cruzi
Fabian Hulpia, Kristof Van Hecke, Cristiane França da Silva, et al.
Journal of Medicinal Chemistry (2018) Vol. 61, Iss. 20, pp. 9287-9300
Open Access | Times Cited: 39
Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug Discovery
Arijit Bhattacharya, Audrey Corbeil, Rubens Lima do Monte‐Neto, et al.
Genes (2020) Vol. 11, Iss. 7, pp. 722-722
Open Access | Times Cited: 37
Short-course combination treatment for experimental chronic Chagas disease
Silvia González, Richard J. Wall, John Thomas, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 726
Open Access | Times Cited: 12
System-based insights into parasitological and clinical treatment failure in Chagas disease
Linda M. Ernst, Giovana C. Macedo, Laura‐Isobel McCall
mSystems (2025)
Closed Access
Human adaptation in the Andes Mountains
Jessica De Loma, Mário Vicente, Noemí Tirado, et al.
(2025)
Open Access
Hit-to-Lead Optimization of a Novel Class of Potent, Broad-Spectrum Trypanosomacides
Stephanie Russell, Raphaël Rahmani, Amy J. Jones, et al.
Journal of Medicinal Chemistry (2016) Vol. 59, Iss. 21, pp. 9686-9720
Open Access | Times Cited: 35
Emerging agents for the treatment of Chagas disease: what is in the preclinical and clinical development pipeline?
Nieves Martínez-Peinado, Núria Cortes-Serra, Irene Losada, et al.
Expert Opinion on Investigational Drugs (2020) Vol. 29, Iss. 9, pp. 947-959
Open Access | Times Cited: 30
Page 1 - Next Page

Scroll to top